Core Viewpoint - Inventiva reported preliminary unaudited financial results for the year ended December 31, 2024, highlighting significant changes in cash position, revenues, and operational activities related to its clinical development of lanifibranor for MASH [1][6]. Financial Results - As of December 31, 2024, the company's cash and cash equivalents were €96.6 million, a substantial increase from €26.9 million in 2023 [2]. - Net cash used in operating activities was (€85.9) million in 2024, up 5.3% from (€81.6) million in 2023 [3]. - R&D expenses decreased by 17% to €90.9 million in 2024 from €110.0 million in 2023, primarily due to a temporary pause in patient recruitment for the NATiV3 trial [3]. - Revenues for 2024 were €9.2 million, down from €17.5 million in 2023, mainly due to milestone payments from CTTQ [11][12]. Business Update - The NATiV3 Phase 3 clinical trial screening was completed in early January 2025, with over 95% of the target patients randomized [13]. - The company plans to focus exclusively on the development of lanifibranor, halting all preclinical research activities and reducing its workforce by approximately 50% [14][15]. Financing Activities - The company generated €145.6 million from financing activities in 2024, a significant increase from €29.1 million in 2023, due to various financing agreements [5]. - The first tranche of structured financing closed with gross proceeds of €116 million, with expectations for additional funding in 2025 [9]. Future Outlook - The company estimates that its current cash position and expected funding will allow it to finance operations until the end of the third quarter of 2026 [9]. - Key upcoming milestones include the randomization of the last patient in the NATiV3 trial and participation in several investor and scientific conferences [17].
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update